Objective evaluation of the role of vincristine in induction and maintenance therapy for myelomatosis. Medical Research Council Working Party on Leukaemia in Adults.

In the Medical Research Council's IVth trial in Myelomatosis the possible benefit of adding vincristine to first line treatment with intermittent melphalan and prednisone has been assessed. This was analysed in 530 patients who were randomly allocated to receive vincristine or not. Survival was...

Descripción completa

Detalles Bibliográficos
Autores principales: MacLennan, I. C., Cusick, J.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1985
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977102/
https://www.ncbi.nlm.nih.gov/pubmed/3896288
_version_ 1782135191069786112
author MacLennan, I. C.
Cusick, J.
author_facet MacLennan, I. C.
Cusick, J.
author_sort MacLennan, I. C.
collection PubMed
description In the Medical Research Council's IVth trial in Myelomatosis the possible benefit of adding vincristine to first line treatment with intermittent melphalan and prednisone has been assessed. This was analysed in 530 patients who were randomly allocated to receive vincristine or not. Survival was not improved by the addition of vincristine. A total of 268 patients reached plateau phase on first line therapy. Of these 226 patients were rerandomised either to continue receiving first line therapy for a further year or to cease therapy. At the present time there is a slight but not significant survival advantage in the group which received no further treatment on reaching plateau.
format Text
id pubmed-1977102
institution National Center for Biotechnology Information
language English
publishDate 1985
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-19771022009-09-10 Objective evaluation of the role of vincristine in induction and maintenance therapy for myelomatosis. Medical Research Council Working Party on Leukaemia in Adults. MacLennan, I. C. Cusick, J. Br J Cancer Research Article In the Medical Research Council's IVth trial in Myelomatosis the possible benefit of adding vincristine to first line treatment with intermittent melphalan and prednisone has been assessed. This was analysed in 530 patients who were randomly allocated to receive vincristine or not. Survival was not improved by the addition of vincristine. A total of 268 patients reached plateau phase on first line therapy. Of these 226 patients were rerandomised either to continue receiving first line therapy for a further year or to cease therapy. At the present time there is a slight but not significant survival advantage in the group which received no further treatment on reaching plateau. Nature Publishing Group 1985-08 /pmc/articles/PMC1977102/ /pubmed/3896288 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
MacLennan, I. C.
Cusick, J.
Objective evaluation of the role of vincristine in induction and maintenance therapy for myelomatosis. Medical Research Council Working Party on Leukaemia in Adults.
title Objective evaluation of the role of vincristine in induction and maintenance therapy for myelomatosis. Medical Research Council Working Party on Leukaemia in Adults.
title_full Objective evaluation of the role of vincristine in induction and maintenance therapy for myelomatosis. Medical Research Council Working Party on Leukaemia in Adults.
title_fullStr Objective evaluation of the role of vincristine in induction and maintenance therapy for myelomatosis. Medical Research Council Working Party on Leukaemia in Adults.
title_full_unstemmed Objective evaluation of the role of vincristine in induction and maintenance therapy for myelomatosis. Medical Research Council Working Party on Leukaemia in Adults.
title_short Objective evaluation of the role of vincristine in induction and maintenance therapy for myelomatosis. Medical Research Council Working Party on Leukaemia in Adults.
title_sort objective evaluation of the role of vincristine in induction and maintenance therapy for myelomatosis. medical research council working party on leukaemia in adults.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977102/
https://www.ncbi.nlm.nih.gov/pubmed/3896288
work_keys_str_mv AT maclennanic objectiveevaluationoftheroleofvincristineininductionandmaintenancetherapyformyelomatosismedicalresearchcouncilworkingpartyonleukaemiainadults
AT cusickj objectiveevaluationoftheroleofvincristineininductionandmaintenancetherapyformyelomatosismedicalresearchcouncilworkingpartyonleukaemiainadults

Ejemplares similares